Zerbaxa Now Indicated for Children
April 21, 2022
Veklury Approved to Treat COVID-19 in Younger Patient Population
April 25, 2022
April 22, 2022 – Pfizer has recalled five lots of Accupril® (quinapril HCl) tablets due to the presence of a nitrosamine identified as above the established acceptable daily intake (ADI) level in recent testing.
- Nitrosamines are potential carcinogens (substances that may cause cancer) found in water and foods. Sustained exposure to them above the ADI may increase an individual’s risk of cancer.
- Accupril is indicated to treat hypertension and as an adjunctive therapy for management of heart failure when added to conventional therapy. As of the recall date, Pfizer has received no reports of adverse events related to the affected product and states that there is no immediate risk to patients taking the medication.
- Pfizer recommends patients reach out to their healthcare provider or pharmacy for help in determining whether the Accupril they are taking is part of the recall. Patients in possession of the affected product should contact Sedgwick at 1-888-345-0481 for return instructions and reimbursement. For help with alternative treatment options, Pfizer has asked patients to contact their healthcare provider.
- A full copy of the recall notice can be found on the FDA’s website